tiprankstipranks

Michael Metzger Insider Profile

4 Followers
Michael Metzger, CEO, Director at Syndax Pharmaceuticals, holds 484.84K shares in Syndax Pharmaceuticals (Ticker: SNDX), holds ― shares in Pyxis Oncology (Ticker: PYXS), holds 0.00 shares in Tobira Therapeutics (Ticker: TBRA).
tipranks
Michael Metzger

Michael Metzger
Syndax Pharmaceuticals (SNDX)
CEO, Director

Ranked #95,846 out of 108,575 Corporate Insiders

Profitable Transactions

40%
2 out of 5 Profitable Transactions

Average Return

-35.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$10M
100.00%
0.00%
0.00%
A breakdown of Michael Metzger's holdings

Insider Roles

Syndax Pharmaceuticals
(SNDX)
CEO, Director
Pyxis Oncology
(PYXS)
Director
Response Genetics
(RGDXQ)
Director
Roles that Michael Metzger holds in companies

Most Profitable Insider Trade

Stock:
Syndax Pharmaceuticals
(SNDX)
Rating:Informative Sell
Date:Feb 10, 2026 - Today
Return:+6.90%
The most profitable trade made by Michael Metzger

Michael Metzger's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Syndax Pharmaceuticals
Jul 09, 2026
CEO, Director
Uninformative Buy
206.55K
$10.07M
Pyxis Oncology
Director
TBRA
Tobira Therapeutics
$0.00
CTIC
CTI BioPharma
Jul 11, 2022
Uninformative Sell
130.99K
$0.00
Response Genetics
Feb 06, 2012
Director
Informative Buy
1.50K
List of latest transactions for each holding click on a transaction to see Michael Metzger's performance on stock

Michael Metzger insider profile FAQ

What is the percentage of profitable transactions made by Michael Metzger?
The percentage of profitable transactions made by Michael Metzger is 40%.
    What is the average return per transaction made by Michael Metzger?
    The average return per transaction made by Michael Metzger is -35.70%.
      What stocks does Michael Metzger hold?
      Michael Metzger holds: SNDX, PYXS, TBRA, CTIC, RGDXQ stocks.
        What was Michael Metzger’s latest transaction?
        Michael Metzger latest transaction was an Uninformative Buy of $206.55K.
          What was Michael Metzger's most profitable transaction?
          Michael Metzger’s most profitable transaction was an Informative Sell of SNDX stock on February 10, 2026. The return on the trade was 6.90%.
            What is Michael Metzger's role in Syndax Pharmaceuticals?
            Michael Metzger's role in Syndax Pharmaceuticals is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.